MaxCyte Inc - רווח נקי למניה ב-12 החודשים האחרונים MXCT

MaxCyte, Inc. (MXCT) develops cell engineering technology, generating steady profits from the sale of proprietary components. This price chart from GURU.Markets illustrates the EPS TTM trend, which stands at 39.10. A Maryland-based facility with a specialized microclimate ensures high product quality, while leadership in electroporation methods provides a sustainable competitive advantage within the gene therapy sector.

For MaxCyte, Inc. (MXCT), the relative YoY (ttm) EPS change serves as an indicator of profitability dynamics over a rolling year. This metric aggregates twelve months of data into a continuous trend, neutralizing quarterly net income volatility. The sensitivity of this indicator allows for a real-time assessment of the efficiency of the consumable cartridge sales and royalty model. A positive vector here confirms the successful scaling of the medtech infrastructure and the growth of recurring margins.